Breakthrough Agents Reshaping RRMM Treatment Landscape

Opinion
Video

Noa Biran, MD, reviews approved bispecific T-cell engagers and how they redefine multiple myeloma treatment, yielding high response rates in refractory cases, but their use necessitates careful evaluation in later therapy lines.

Recent Videos
3 experts are featured in this series.
3 experts are featured in this series.
4 experts are featured in this series.
6 experts are featured in this series.
6 experts are featured in this series.
4 experts are featured in this series.
Related Content
Noa Biran, MD, speaks about recently approved bispecific therapies and current trials that may impact the standard of care in relapsed/refractory multiple myeloma.

Optimizing Novel Treatment Options in Relapsed/Refractory Multiple Myeloma

Russ Conroy
March 4th 2024
Article

Noa Biran, MD, speaks about recently approved bispecific therapies and current trials that may impact the standard of care in relapsed/refractory multiple myeloma.